Alpha 2.0
Login Register
» Authors » Kim Barbara Luley

Kim Barbara Luley

Explore the profile of Kim Barbara Luley including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 359
Followers 0
Related Specialties
Oncology
Hematology
Top 10 Co-Authors
Claudia Pauligk
Sylvie Lorenzen
Salah-Eddin Al-Batran
Stephan Probst
Niklas Gebauer
Dirk Rades
Veronica Bernard
Peter Thuss-Patience
Christoph Thorns
Hendrik Lehnert
Published In
Leuk Lymphoma
Int J Cancer
Lancet Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy
Masetti M, Al-Batran S, Goetze T, Thuss-Patience P, Riera Knorrenschild J, Goekkurt E, et al.
Int J Cancer . 2024 Mar; 154(12):2142-2150. PMID: 38447003
FOLFOX plus nivolumab represents a standard of care for first-line therapy of advanced gastroesophageal cancer (aGEC) with positive PD-L1 expression. The efficacy of second-line VEGFR-2 inhibition with ramucirumab (RAM) plus...
2.
Phase III randomized, double-blind study of paclitaxel with and without everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)
Lorenzen S, Riera Knorrenschild J, Pauligk C, Hegewisch-Becker S, Seraphin J, Thuss-Patience P, et al.
Int J Cancer . 2020 Apr; 147(9):2493-2502. PMID: 32339253
The RADPAC trial evaluated paclitaxel with everolimus in patients with advanced gastroesophageal cancer (GEC) who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen. Patients were randomly assigned to receive paclitaxel...
3.
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma...
Al-Batran S, Hofheinz R, Pauligk C, Kopp H, Haag G, Luley K, et al.
Lancet Oncol . 2016 Oct; 17(12):1697-1708. PMID: 27776843
Background: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma, but has not yet been evaluated in the context of resectable patients. Here we report findings from the...
4.
Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support
Gebauer N, Biersack H, Czerwinska A, Schemme J, Hardel T, Bernard V, et al.
Leuk Lymphoma . 2015 Sep; 57(6):1482-6. PMID: 26414189
No abstract available.
5.
Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspective
Gebauer N, Biersack H, Czerwinska A, Schemme J, Hardel T, Bernard V, et al.
Leuk Lymphoma . 2015 May; 57(1):226-9. PMID: 25947035
No abstract available.